105 related articles for article (PubMed ID: 12413836)
1. Synthesis of derivatives of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) modified at the 1-aromatic moiety as novel NMDA receptor antagonists: the aromatic group is essential for the activity.
Kazuta Y; Tsujita R; Yamashita K; Uchino S; Kohsaka S; Matsuda A; Shuto S
Bioorg Med Chem; 2002 Dec; 10(12):3829-48. PubMed ID: 12413836
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) derivatives modified at the carbamoyl moiety as a new class of NMDA receptor antagonists.
Kazuta Y; Tsujita R; Ogawa K; Hokonohara T; Yamashita K; Morino K; Matsuda A; Shuto S
Bioorg Med Chem; 2002 Jun; 10(6):1777-91. PubMed ID: 11937336
[TBL] [Abstract][Full Text] [Related]
3. (1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy.
Shuto S; Yoshii K; Matsuda A
Jpn J Pharmacol; 2001 Mar; 85(3):207-13. PubMed ID: 11325012
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S, 2R)-1-phenyl-2-[(R)-1-amino-2-propynyl]-N,N- diethylcyclopropanecarboxamide is a novel class of NMDA receptor channel blocker.
Shuto S; Ono S; Imoto H; Yoshii K; Matsuda A
J Med Chem; 1998 Aug; 41(18):3507-14. PubMed ID: 9719604
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxami de, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist.
Shuto S; Ono S; Hase Y; Ueno Y; Noguchi T; Yoshii K; Matsuda A
J Med Chem; 1996 Nov; 39(24):4844-52. PubMed ID: 8941398
[TBL] [Abstract][Full Text] [Related]
6. Conformational analysis of the NMDA receptor antagonist (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) designed by a novel conformational restriction method based on the structural feature of cyclopropane ring.
Ono S; Ogawa K; Yamashita K; Yamamoto T; Kazuta Y; Matsuda A; Shuto S
Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):966-8. PubMed ID: 12130856
[TBL] [Abstract][Full Text] [Related]
7. Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity.
Noguchi T; Ishii K; Ohtubo Y; Shuto S; Ono S; Matsuda A; Yoshii K
Synapse; 1999 Feb; 31(2):87-96. PubMed ID: 10024005
[TBL] [Abstract][Full Text] [Related]
8. (+/-)-(Z)-2-(aminomethyl)-1-phenylcyclopropanecarboxamide derivatives as a new prototype of NMDA receptor antagonists.
Shuto S; Takada H; Mochizuki D; Tsujita R; Hase Y; Ono S; Shibuya N; Matsuda A
J Med Chem; 1995 Jul; 38(15):2964-8. PubMed ID: 7636857
[TBL] [Abstract][Full Text] [Related]
9. Establishment of CHO cell lines expressing four N-methyl-D-aspartate receptor subtypes and characterization of a novel antagonist PPDC.
Uchino S; Watanabe W; Nakamura T; Shuto S; Kazuta Y; Matsuda A; Nakajima-Iijima S; Kudo Y; Kohsaka S; Mishina M
FEBS Lett; 2001 Oct; 506(2):117-22. PubMed ID: 11591383
[TBL] [Abstract][Full Text] [Related]
10. Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.
Tamiya J; Dyck B; Zhang M; Phan K; Fleck BA; Aparicio A; Jovic F; Tran JA; Vickers T; Grey J; Foster AC; Chen C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3328-32. PubMed ID: 18445525
[TBL] [Abstract][Full Text] [Related]
11. A method for designing conformationally restricted analogues based on allylic strain: synthesis of a novel class of noncompetitive NMDA receptor antagonists having the acrylamide structure.
Ohmori Y; Yamashita A; Tsujita R; Yamamoto T; Taniuchi K; Matsuda A; Shuto S
J Med Chem; 2003 Dec; 46(25):5326-33. PubMed ID: 14640541
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist.
Reddy NL; Hu LY; Cotter RE; Fischer JB; Wong WJ; McBurney RN; Weber E; Holmes DL; Wong ST; Prasad R
J Med Chem; 1994 Jan; 37(2):260-7. PubMed ID: 8295213
[TBL] [Abstract][Full Text] [Related]
13. trans-2-Aryl-N,N-dipropylcyclopropylamines: synthesis and interactions with 5-HT(1A) receptors.
Vallgårda J; Appelberg U; Arvidsson LE; Hjorth S; Svensson BE; Hacksell U
J Med Chem; 1996 Mar; 39(7):1485-93. PubMed ID: 8691479
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (+/-)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype.
Guzikowski AP; Tamiz AP; Acosta-Burruel M; Hong-Bae S; Cai SX; Hawkinson JE; Keana JF; Kesten SR; Shipp CT; Tran M; Whittemore ER; Woodward RM; Wright JL; Zhou ZL
J Med Chem; 2000 Mar; 43(5):984-94. PubMed ID: 10715162
[TBL] [Abstract][Full Text] [Related]
15. New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.
Liégeois JF; Eyrolles L; Ellenbroek BA; Lejeune C; Carato P; Bruhwyler J; Géczy J; Damas J; Delarge J
J Med Chem; 2002 Nov; 45(23):5136-49. PubMed ID: 12408724
[TBL] [Abstract][Full Text] [Related]
16. Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.
Kazuta Y; Hirano K; Natsume K; Yamada S; Kimura R; Matsumoto S; Furuichi K; Matsuda A; Shuto S
J Med Chem; 2003 May; 46(10):1980-8. PubMed ID: 12723960
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D(2), serotonin, and GABA(A) receptors.
Asproni B; Pau A; Bitti M; Melosu M; Cerri R; Dazzi L; Seu E; Maciocco E; Sanna E; Busonero F; Talani G; Pusceddu L; Altomare C; Trapani G; Biggio G
J Med Chem; 2002 Oct; 45(21):4655-68. PubMed ID: 12361392
[TBL] [Abstract][Full Text] [Related]
18. New selective and potent 5-HT(1B/1D) antagonists: chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides.
Liao Y; Böttcher H; Harting J; Greiner H; van Amsterdam C; Cremers T; Sundell S; März J; Rautenberg W; Wikström H
J Med Chem; 2000 Feb; 43(3):517-25. PubMed ID: 10669578
[TBL] [Abstract][Full Text] [Related]
19. Preferred antagonist binding state of the NMDA receptor: synthesis, pharmacology, and computer modeling of (phosphonomethyl)phenylalanine derivatives.
Dorville A; McCort-Tranchepain I; Vichard D; Sather W; Maroun R; Ascher P; Roques BP
J Med Chem; 1992 Jul; 35(14):2551-62. PubMed ID: 1386112
[TBL] [Abstract][Full Text] [Related]
20. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
